TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Serum NGAL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolite concentrations related to fat metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolite concentrations related to lipolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolite concentrations related to TCA cycle intermediates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hippocampal responses to emotional stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PIVKA-II level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of PIVKA-II for HCC diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure-time product (PTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postoperative urine glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Average daily protein/creatinine ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Blood total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in number of days of headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length of active and second stages of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perineal integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: maternal and neonatal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: large heart rate characteristics spikes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suspected or proven infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: respiratory deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: inflammation level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eradication rate of M genitalium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Quality-adjusted life-year (QALY) saved
Endpoint domain: Resource use
Primary endpoint: Change in distress levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle thickness of the arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circumference of the arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subcutaneous tissue thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VCSS scores at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AVVQ scores at 6 weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AVVQ scores at 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: F-wave parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: weight loss >= 2 kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight gain >= 1 kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local tumour control probability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Left Ventricular Ejection Fraction (EF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: health-related quality of life (CRDQ and SGRQ-I)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mucositis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 48-hour red blood cell (RBC) transfusion requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: need for massive transfusion over 48 hours (>20 RBC units)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 30-day risk of acute respiratory distress syndrome (ARDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: plasma 8‐isoprostane concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Annualized bleeding rates (ABRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of mental health care contacts
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of rebleeding from the access site
Endpoint domain: Adverse events/effects
Primary endpoint: Stroke or vascular death
Endpoint domain: Mortality/survival
Primary endpoint: Stroke in territory
Endpoint domain: Mortality/survival
Primary endpoint: pleural thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patient's self-rated CES-D scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physicians' ratings of depression severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased GM volume in vmPFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increased impulsivity trait
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean slow velocity (SPV) of downbeat nystagmus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: odds of cocaine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interfragmentary motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fracture rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first request for supplemental analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: any stroke
Endpoint domain: Mortality/survival
Primary endpoint: Eosinophils reduction in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: QOLIE‐89 overall score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Induction-delivery interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Willingness to take lithium for fracture healing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge about side effects of lithium
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of CoQ10 at 2,700 mg/day compared to placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: internal attributions in other-referent contexts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h posttransfusion increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CCI (Clinical Composite Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative nausea and vomiting (PONV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: target bifurcation failure
Endpoint domain: Adverse events/effects
Primary endpoint: minimal lumen diameter at SB ostium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TEWL values on stripped human skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of PGP9.5 and TRPV1 immunoreactive nerve fibres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: muscle strength around affected joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: muscle strength around unaffected joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to Untreated Progression (TTUP)
Endpoint domain: Mortality/survival
Primary endpoint: Relative risk of symptom onset following heavy physical exertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of coronary occlusion following vigorous exertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinical seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: receptive language
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: behavioral hyperactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight gain by more than 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impaired glucose tolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of trazodone for psychogenic impotence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alcohol-induced cigarette craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cigarette-induced cigarette craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dorsiflexion range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Passive resistive torque of the plantar flexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral CD34 positive cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nonfatal myocardial infarctions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: neuro-ventilatory efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuro-mechanical efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VSA score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospital length-of-stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: renal parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Documentation accuracy of seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean residence time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delivery and absorption in the ileum and colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of exclusive breastfeeding one month after birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic equivalence (AUC0–inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity (anti-drug antibodies)
Endpoint domain: Adverse events/effects
Primary endpoint: Kansas City Cardiomyopathy clinical summary
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total and LDL cholesterol reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose total area under the curve reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: thalamic asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: improvement of limb activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of amyloid A protein quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of amyloid A protein quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage improvement in lesional transcriptomic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Clinical changes in lesion severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: length of stay at the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: functional task performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: paresthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to tuberculosis medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported maximum bone pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in physical IPV use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in psychological IPV use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in controlling behaviors involving isolation and monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of acetylcholinesterase inhibitors (AChIs)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Use of memantine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Serum lipid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in PLMS and RLS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readmission rates within three months
Endpoint domain: Mortality/survival
Primary endpoint: Length of care
Endpoint domain: Resource use
Primary endpoint: Parental coping
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hospital admissions for cardiovascular causes
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Admissions per 1,000 subject‐years for cardiovascular disease
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Symptomatic intracranial hemorrhage rates
Endpoint domain: Adverse events/effects
Primary endpoint: Early neurologic recovery at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional outcome at 90 days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain scores at rest and on movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma drug concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Plasma levels of cortisol and stress-metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: SV graft patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RQLQ score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: RMS improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in TFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MRSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HAQ-DI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Anti-HAV geometric mean concentrations (GMCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Local and systemic reactions related to vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: ASQ‐3 communication scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: ASQ‐3 personal and social scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: ASQ‐3 fine motor scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean sevoflurane MAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of dream recall
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: visible plaque index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bleeding gingival index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: circulating proinflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dose-dependent impairment in performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of IMT(mean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in benzodiazepine prescribing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General health questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of excellent bowel preparation (BBPS=9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events (abdominal fullness)
Endpoint domain: Adverse events/effects
Primary endpoint: incident clinical fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiographic vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in aBMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of new ACE lesions
Endpoint domain: Adverse events/effects
Primary endpoint: Minor bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: venous peak velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: time-averaged maximum velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: volume flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean gradients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular mass regression (LVMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NS5 reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: N1 suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sensitivity of clinical decision rule for high ICP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: sustained relief at 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean improvement on 0 to 10 scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: postoperative pain score at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary blood flow (CBF) response to acetylcholine (Ach)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total microstrains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative events of depressive episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drop in depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-24 for tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative ABG closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of postoperative ABG of 20 dB or less
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DXA scan rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical dilation reached with priming
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of difficulty in cervical dilation assessed by the surgeon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mild discomfort after insertion
Endpoint domain: Adverse events/effects
Primary endpoint: IL-2 and IFN-γ production levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of LFX-resistant MTB isolates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: High-level LFX resistance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of isolates with mutations in gyrA gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Fasting Plasma Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes